EpimAb Biotherapeutics - About the company
EpimAb Biotherapeutics is a series C company based in Shanghai (China), founded in 2015. It operates as a Bispecific antibody therapies using its proprietary FIT-Ig platform. EpimAb Biotherapeutics has raised $219M in funding from investors like CMB International Capital, Mirae Asset and Yuanhe Holdings. The company has 3416 active competitors, including 1160 funded and 817 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alexion and Sana Biotechnology.
Company Details
EpimAb Biotherapeutics is a privately owned R&D company focussed on developing bispecific antibody therapeutics with its proprietary technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). The technology re-arranges the DNA sequences of two MAbs into three constructs and co-expressing them in mammalian cells, it generates bi-specific FIT-Igs that fully retain the biological function of their parental MAbs.It is currently creating a pipeline of its own bispecific antibody therapeutics focused around immuno-oncology. It has collaboration with Innovent Biologics to develop Multi-Target Bispecific Antibody. Their lead candidate is EMB-01 a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig, which according to company claims has shown promising results in multiple preclinical cancer models.
- Website
- epimab.com/en
- Social
- Email ID
- *****@epimab.com
Key Metrics
Founded Year
2015
Location
Shanghai, China
Stage
Series C
Total Funding
$219M in 3 rounds
Latest Funding Round
Investors
Ranked
454th among 3416 active competitors
Similar Companies
Sign up to download EpimAb Biotherapeutics' company profile
EpimAb Biotherapeutics's funding and investors
EpimAb Biotherapeutics has raised a total funding of $219M over 3 rounds. Its first funding round was on Apr 25, 2017. Its latest funding round was a Series C round on Mar 22, 2021 for $*****. 12 investors participated in its latest round. EpimAb Biotherapeutics has 15 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of EpimAb Biotherapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 22, 2021 | 9805315 | Series C | 3643341 | 9831670 | 9563511 | 7701174 |
Jun 05, 2019 | 5008399 | Series B | 3446680 | 3282811 | 6103654 | |
Apr 25, 2017 | 6705945 | Series A | 7251706 | 8566564 |
Access funding benchmarks and valuations. Sign up today!View details of EpimAb Biotherapeutics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
EpimAb Biotherapeutics's Competitors and alternates
Top competitors of EpimAb Biotherapeutics include Jazz Pharmaceuticals, Alexion and Sana Biotechnology. Here is the list of Top 10 competitors of EpimAb Biotherapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 79/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
4th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 74/100 | ||
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
10th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
454th | EpimAb Biotherapeutics 2015, Shanghai (China), Series C | Bispecific antibody therapies using its proprietary FIT-Ig platform | $219M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on EpimAb Biotherapeutics's competitors? Click here to see the top ones
EpimAb Biotherapeutics's Investments and acquisitions
EpimAb Biotherapeutics has made no investments or acquisitions yet.
News related to EpimAb Biotherapeutics
Filter this listMedia has covered EpimAb Biotherapeutics for 1 event in last 1 year.
•
•
•
Medigene and EpimAb to develop T cell engagers for solid tumoursPharmaceutical Technology•Feb 28, 2025•Medigene, EpimAb Biotherapeutics
•
•
•
•
Vignette Bio’s License Agreement with EpimAb BiotherapeuticsGlobal Legal Chronicle•Sep 12, 2024•, EpimAb Biotherapeutics, Gunderson Dettmer
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about EpimAb Biotherapeutics
Explore our recently published companies
- Leica Rumors - 2008 founded, Unfunded company
- Bake Or Break - 2006 founded, Unfunded company
- Martinez Landscaping - United States based, 1989 founded, Unfunded company
- Peak Asphalt - United States based, 1997 founded, Unfunded company
- Imagicle - Massarosa based, 2010 founded, Unfunded company
- iDO Devices - Noida based, 2025 founded, Seed company
